12 completed, 4 unknown, 2 recruiting, 2 terminated. 22 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 12, Unknown 4, Recruiting 2, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
Follow Epoetin Alfa: new trials by email Literature Review of Epoetin Alfa trials Research Report on Epoetin Alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy Volunteers Erythropoietin alfa - Pharmacokinetics and Pharmacodynamics in Healthy Volunteers | Phase 1 | Not yet recruiting | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 44 | 2026-09-01 | 2026-08-03 |
| EVR and EPO for Liver Transplant Tolerance Everolimus, Epoetin alfa - Liver Transplant | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-01-21 | 2026-04-06 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA Luspatercept Injection [Reblozyl], Eprex - MDS, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Groupe Francophone des Myelodysplasies | 150 | 2022-05-18 | 2026-09-29 |
| A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002 Erythropoietin alpha - Natural Blood and Blood Product Toxicity | Phase 1 / Phase 2 | Completed | Globe Biotech Limited | 42 | 2021-10-16 | 2022-10-20 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Vadadustat, Darbepoetin alfa, Epoetin alfa - Anemia Associated With Chronic Kidney Disease | Phase 1 | Completed | Akebia Therapeutics | 46 | 2019-05-28 | 2020-09-16 |
| Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents EPREX, sodium chloride AGUETTANT 0.9% - Sports Drug Abuse | Phase 1 | Unknown | Association Athletes For Transparency | 24 | 2017-09-08 | 2017-09-08 |
| Generation of Positive Biological Samples to Epoetin for Doping Control. EPOETIN ALFA - There Are no Conditions Under Study. Healthy Volunteers | Phase 1 | Completed | Parc de Salut Mar | 2 | 2016-11-30 | 2017-10-05 |
| To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers EPORON, EPREX - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 42 | 2015-11-01 | 2015-10-20 |
| EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT) Epogen, Normal Saline - Cardiac Surgery-CABG, Cardiac Valve Replacement | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 4 | 2015-05-01 | 2019-02-26 |
| Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Erythropoietin, Normal saline - Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 50 | 2013-09-01 | 2020-07-13 |
| PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin Alfa - Healthy | Phase 1 | Completed | Azidus Brasil | 80 | 2013-02-28 | 2022-10-28 |
| PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects. Epoetin Alfa - Healthy | Phase 1 | Completed | Azidus Brasil | 28 | 2013-02-28 | 2022-10-31 |
| PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects Epoetin Alfa - Healthy | Phase 1 | Unknown | Azidus Brasil | 28 | 2013-02-01 | 2012-08-14 |
| PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects. Epoetin Alfa - Healthy | Phase 1 | Unknown | Azidus Brasil | 80 | 2013-02-01 | 2012-08-14 |
| Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects. Eritromax, Eprex - Renal Insufficiency, Chronic | Phase 1 | Completed | Azidus Brasil | 40 | 2012-11-01 | 2022-11-03 |
| A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Epoetin Hospira, Epogen - Chronic Renal Failure | Phase 1 | Completed | Hospira, now a wholly owned subsidiary of Pfizer | 107 | 2010-07-01 | 2017-03-20 |
| Neonatal Erythropoietin in Asphyxiated Term Newborns erythropoietin - Hypoxic-ischemic Encephalopathy | Phase 1 | Completed | University of California, San Francisco | 24 | 2010-01-01 | 2012-11-09 |
| TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study Erythropoetin (rHuEPO, EPREX®) - Spinal Trauma With Neurological Deficit | Phase 1 | Withdrawn | Hospices Civils de Lyon | 20 | 2007-05-01 | 2009-03-11 |
| Erythropoetin Neuroprotection for Neonatal Cardiac Surgery Erythropoetin, Normal saline - Congenital Heart Disease, Hypoplastic Left Heart Syndrome | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 62 | 2006-09-01 | 2020-02-07 |
| A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease epoetin alfa - Chronic Kidney Disease, Anemia | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 40 | 2006-01-01 | 2011-05-18 |
Showing 20 of 22. Sign in to see all of them.
Anemia (3) · Renal Insufficiency, Chronic (3) · Asphyxia Neonatorum (2) · Hypoxia-Ischemia, Brain (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Burkitt Lymphoma (1) · HIV Infections (1) · Heart Defects, Congenital (1) · Hypoplastic Left Heart Syndrome (1) · Kidney Failure, Chronic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
Azidus Brasil (5) · University of California, San Francisco (2) · Akebia Therapeutics (1) · Amgen (1) · Association Athletes For Transparency (1) · Baylor College of Medicine (1) · Dong-A ST Co., Ltd. (1) · Globe Biotech Limited (1) · Groupe Francophone des Myelodysplasies (1) · Hospices Civils de Lyon (1) · Hospira, now a wholly owned subsidiary of Pfizer (1) · Johns Hopkins University (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Nanogen Pharmaceutical Biotechnology Joint Stock Company (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (9) · Brazil (5) · Bangladesh (1) · France (1) · Italy (1) · South Korea (1)
Yvonne W Wu, MD, MPH (2) · Alexandre Frederico, PI (1) · Dean B. Andropoulos, M.D. (1) · Hyung-gi Lee, MD, Ph.D (1) · In-jin Jang, MD, Ph.D (1) · Jane N. Winter, MD (1) · Ju-yeon Cho, Ph.D (1) · Keith A. Horvath, MD (1) · Kyung-sang Yu, MD, Ph.D (1) · Mamun Al Mahtab, PhD (1) · Miles SA (1) · Paolo Cravedi, M.D., Ph.D. (1)
PMID 23008465, PMID 23102686, PMID 24524452, PMID 25439577, PMID 30661082, PMID 31261373, PMID 36005278, PMID 40790188
2016 (1), R21HD055501 (1)